T0	Participants 37 114	early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy.
T1	Participants 309 341	Type 2 diabetic patients (N.=57)
T2	Participants 436 465	Diabetic nephropathy patients
T3	Participants 808 822	diabetic group
T4	Participants 925 959	diabetic group without nephropathy
T5	Participants 1303 1336	type 2 diabetes mellitus patients
T6	Participants 1393 1401	patients